Comparison of the effect of atorvastatin and rosuvastatin on reducing LDL

Comparison of the effect of atorvastatin and rosuvastatin on reducing LDL in type 2 diabetic patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151020024625N22

Enrollment

128

Registered

2024-10-15

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia. Lipoprotein deficiency

Interventions

Intervention 1: Intervention group 1: 30 patients will receive atorvastatin (20 mg/daily) for 4 months. Intervention 2: Intervention group 2: 30 patients will receive atorvastatin (40mg/daily) for 4

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes treated by oral agents

Exclusion criteria

Exclusion criteria: Patients with cancer Chronic inflammatory and infectious diseases Renal failure Liver failure

Design outcomes

Primary

Measure	Time frame
Alteration in LDL-C levels. Timepoint: Before and 4 months after intervention. Method of measurement: Laboratory method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Rastegar

Semnan University of Medical Sciences

Godsierastegar@gmail.com+98 23 3142 2119

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026